Brief: AFT Pharmaceuticals Enters Exclusive Development, License And Supply Agreement With Mikasaseiyaku
28/09/2026 02:41
BRIEF-AFT Pharmaceuticals Enters Exclusive Development, License And Supply Agreement With Mikasaseiyaku Sept 28 (Reuters) - AFT Pharmaceuticals Ltd AFT.NZ:
ENTERED INTO AN EXCLUSIVE DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT WITH MIKASASEIYAKU
UNDER DEAL, AFT GRANTS MIKASA EXCLUSIVE LICENSE TO SEEK MARKETING AUTHORIZATION, COMMERCIALIZE PRODUCT THROUGHOUT JAPAN
DEAL FOR DEVELOPMENT AND COMMERCIALIZATION OF AFT'S INTRAVENOUS FIXED-DOSE COMBINATION ANALGESIC, MAXIGESIC IV IN JAPAN
Further company coverage: AFT.NZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AFT Pharmaceuticals
See all newsNZ's AFT Pharma eyes highest weekly gain in over 2 months after results
Brief: AFT Pharmaceuticals Reports Double Digit Revenue Growth In 1H FY27
NZ's AFT Pharmaceuticals gains most in over 2 weeks on strong half-year results
Brief: AFT Pharmaceuticals Enters Exclusive Development, License And Supply Agreement With Mikasaseiyaku
NZ's AFT Pharma rises to near 1-month high on Japan licensing deal for Maxigesic IV